PROVIDER BULLETIN PROVIDER INFORMATION



July 2, 2018

New Site of Care Drug Management Program for Infused and Injectable Drugs Administered by a Health Care Provider

Effective September 3, 2018, select specialty medications that are already subject to prior authorization (PA) requirements for Commercial subscribers will be included in the Site of Care Drug Management Program. Within the program, infused and injectable specialty medications administered by a health care provider are required to be administered in a clinic, infusion center, or by a home infusion agency. Site of Care criteria will be added to existing drug policies and PA requirements and reviews can be submitted beginning August 20, 2018.

Infusions or injections administered in a hospital outpatient setting for medications subject to PA requirements are not eligible for reimbursement unless the medical necessity criteria have been met. No partial approvals will be granted.

Prior Authorizations requests must include the following additional information:

- Site of care location:
 - Infusion agency in the Home
 - Clinic/Office
 - Infusion Center
 - Hospital outpatient, if selected requires an exception reason to be provided based on medical policy criteria

Please check the subscriber's benefits and confirm the **in-network** site of care. All new requests and upon renewal, drug PAs will be subject to site of care management unless otherwise stated in the medical policy criteria.

List of Medications and the medical policy number:

- Abatacept, II-161
- Agalsidase Beta, II-26
- Alemtuzumab, II-184 (non-oncologic indications only)
- Alglucosidase Alfa, II-186
- Certolizumab Pegol, II-179
- Edaravone, II-178
- Golimumab (Simponi Aria), II-180
- Immunoglobulin Therapy, II-51
- Infliximab, II-97
- Natalizumab, II-49
- Ocrelizumab, II-185
- Rituximab, II-47 (non-oncologic indications only)
- Sebelipase Alfa, II-200
- Tocilizumab, II-181 (non-oncologic indications only)
- Ustekinumab, II-168
- Vedolizumab, II-182

Bulletin P27-18

Distribution: Available on website: <u>https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications</u>

Blue Cross[®] and Blue Shield[®] of Minnesota and Blue Plus[®] are nonprofit independent licensees of the Blue Cross and Blue Shield Association. L08R04 (12/13)

Continued

For more information, please visit:

Procedures/Services/Drugs under the medical benefit:

- Go to: providers.bluecrossmn.com
- Under Tools and Resources, select "Medical Policy" and acknowledge the Acceptance statement
- Select the "+" plus sign next to the Medical and Behavioral Health Policies
- Under the "Medical Policy Supporting Documents", Click on the Site of Care link, available after August 1, 2018

Products Impacted

- This program only applies to commercial lines of business. As a reminder for a value network subscriber, please have the subscriber call Blue Cross at (651) 662-5200 or 1-800-262-0820.
- The changes do not impact subscribers who have coverage through Prepaid Medical Assistance Program (PMAP), MinnesotaCare, SecureBlue (MSHO), Minnesota Senior Care Plus (MSC+), Federal Employee Program (FEP), Medicare Advantage or Platinum Blue as those lines of business have separate PA requirements.

Submitting a Medical Drug PA Request

Providers must submit a PA request for approval for the medical specialty drugs listed above. If a provider does not obtain required PA before rendering services, Blue Cross will deny claims as provider liability for lack of prior authorization. The requirement applies to subscribers starting drug therapy and to those already being treated with one of the medications above.

Before submitting a PA request, providers are asked to check the Medical Policy criteria and attach **all required clinical documentation** with the request including documentation of previous therapies tried and evidence of symptom improvement using the drug. PA requests will be reviewed when patient-specific, relevant medical documentation has been provided supporting the medical necessity of the drug. Failure to submit required information may result in review delays (if outreach is needed to obtain missing clinical information) or a denial of the request due insufficient information.

Providers can submit an electronic medical drug (ePA) request:

- Online via our free <u>Availity</u> provider portal for Blue Cross to review
- Using a <u>NCPDP</u> standard XML file feed to Blue Cross through CenterX, via an integrated Electronic Medical Record (EMR) system. To learn how to do this, providers should contact their EMR vendor for assistance.
- Out of state, non-contracted providers can use the process above, the <u>Minnesota Uniform Form for PA Request</u> <u>and Formulary Exceptions</u> fax form located under the Forms section on the Blue Cross website, or submit the PA request to Blue Cross using their own form (secure fax: 651.662.2810).

Questions?

If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.